# Repurposing minocycline as an added-on treatment for ulcerative colitis patients on mesalamine: a randomized clinical pilot study

## TL;DR

This study explores adding minocycline to mesalamine treatment for ulcerative colitis, finding it improves symptoms and reduces inflammation.

## Contribution

The novel contribution is evaluating minocycline as an adjunct treatment for UC patients already on mesalamine.

## Key findings

- Minocycline group showed lower levels of MMP-12, ICAM-1, and NO compared to mesalamine group.
- Patients in the minocycline group had improved clinical outcomes and quality of life metrics.
- Minocycline appears to modulate inflammation and enhance treatment effectiveness in UC.

## Abstract

One of the most prevalent forms of chronic inflammatory bowel disease is ulcerative colitis (UC). The key characteristics observed in UC patients involve fecal urgency, abdominal discomfort, and bloody diarrhea, all of which significantly lower their quality of life. Preclinical studies investigated the protective effect of minocycline in animal models of colitis. This study aimed to assess minocycline’s potential efficacy and safety in mesalamine-treated UC patients. This randomized, controlled pilot clinical research included 46 individuals with mild to moderate UC who met the inclusion criteria. The mesalamine group (n = 23) received 1 g of mesalamine three times a day for 6 months. The minocycline group (n = 23) received minocycline 100 mg twice daily and mesalamine 1 g three times a day. Patients were evaluated by a gastroenterologist using the Short Inflammatory Bowel Disease Questionnaire (SIBDQ), Truelove and Witts Severity Index, Brief Pain Inventory (BPI), and the non-invasive Partial Mayo Score (PMS). Before and after 6 months of treatment, each patient’s levels of nitric oxide (NO), matrix metalloproteinase-12 (MMP-12), and intracellular adhesion molecule 1 (ICAM-1) were measured. Serum levels of MMP-12, ICAM-1, and NO were statistically lower in the minocycline group than in the mesalamine group. In the minocycline group, the Truelove and Witts Severity Index, PMS, and BPI pain intensity all significantly dropped, whereas SIBDQ was substantially elevated compared to the mesalamine group. Minocycline could serve as a potential adjunctive remedy for enhancing clinical outcomes, improving quality of life, and modulating inflammation in patients with mild to moderate UC.

Trial registration: ClinicalTrials.gov ID: NCT06201793. Trial registration date 22–1-2024.